Gary B. Gordon, M.D., Ph.D., is an accomplished pharmaceutical executive and strategic business leader with extensive experience in the development of drugs from first in-human studies to approval and commercialization. He brings innovative approaches to the process, leveraging advantageous regulatory pathways and close collaborations with investigators, patient advocacy groups and key academic and government consortiums.
Recently, Dr Gordon served as the Vice President, Oncology Department at AbbVie (a spin-off of Abbott), where he oversaw the development of AbbVie’s oncology projects. He drove drug development innovations, expanded the staff and advanced the Oncology pipeline. He played a critical role in the oncology business expansion, leading to Abbvie’s current position in Oncology. This includes the approval of venetoclax, several major acquisitions and other collaborations. Gary was on the Abbvie-Genentech team that received the 2017 Prix Galien award for the Best Pharmaceutical Product.
Dr. Gordon joined Abbott in 2003 as Global Project Head, rapidly advancing to the role of Divisional Vice President, Global Oncology Development.
Prior to AbbVie, Gary was Chief Scientific Officer and Vice President of Clinical Affairs at Ovation Pharmaceuticals from 2001 to 2003. In this role, he helped obtain funding and five on market products.
He entered the pharmaceutical industry in 1995, joining the G.D. Searle division of Monsanto, which eventually became part of Pharmacia. Dr. Gordon’s responsibilities included programs related to COX-2 inhibitors for the prevention and treatment of cancer, the development of angiogenesis inhibitors, and involvement in the hematopoietic and cancer immunization programs. He also helped establish a tissue bank and an Industry Academic interface program. He also co-chaired an AACR task force focused on the treatment and prevention of intraepithelial neoplasias.